Rosiglitazone enhances learning, place cell activity, and synaptic plasticity in middle-aged rats.

Autor: Wang BW; Trinity College Institute of Neuroscience, Trinity College, Dublin, Ireland., Hok V, Della-Chiesa A, Callaghan C, Barlow S, Tsanov M, Bechara R, Irving E, Virley DJ, Upton N, O'Mara SM
Jazyk: angličtina
Zdroj: Neurobiology of aging [Neurobiol Aging] 2012 Apr; Vol. 33 (4), pp. 835.e13-30. Date of Electronic Publication: 2011 Oct 04.
DOI: 10.1016/j.neurobiolaging.2011.08.013
Abstrakt: As an antidiabetic agent, rosiglitazone (ROSI) binds and activates peroxisome proliferator-activator receptor gamma (PPARγ), altering the expression of genes involved in glucose uptake and disposal, ultimately affecting glucose regulation. ROSI might therefore be a potential treatment to ameliorate age-related decline in cognitive function, particularly on an insulin-resistant background, where improvements in peripheral insulin sensitivity and central nervous system (CNS) glucose utilization may facilitate recovery of cognitive function. We therefore examined the amelioration potential of ROSI for neurocognitive deficits resulting from aging in an animal model. Behaviorally, acute and chronic ROSI treatments enhanced acquisition of learning in the water plus maze, a modified version of the Morris water maze task. In parallel, restoration of synaptic plasticity in the dentate gyrus of ROSI-treated middle-aged rats was evident after a single dose intake. Additionally, the spatial receptive fields of hippocampal CA1 place cells were significantly improved by chronic ROSI administration. ROSI treatment reversed basal plasma insulin abnormalities and increased hippocampal glucose transporter (GLUT)-3 expression in middle-aged rats. Taken together, these results suggest that ROSI modulates hippocampal circuitry effectively to promote an improvement in cognitive function, possibly via a glucose transporter-3 mechanism.
(Copyright © 2012 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: